[go: up one dir, main page]

SMT201600229B - - Google Patents

Info

Publication number
SMT201600229B
SMT201600229B SM201600229T SM201600229T SMT201600229B SM T201600229 B SMT201600229 B SM T201600229B SM 201600229 T SM201600229 T SM 201600229T SM 201600229 T SM201600229 T SM 201600229T SM T201600229 B SMT201600229 B SM T201600229B
Authority
SM
San Marino
Application number
SM201600229T
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of SMT201600229B publication Critical patent/SMT201600229B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0603—Embryonic cells ; Embryoid bodies
    • C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/462—Igs containing a variable region (Fv) from one specie and a constant region (Fc) from another
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/02—Animal zootechnically ameliorated
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0381—Animal model for diseases of the hematopoietic system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/30—Vector systems comprising sequences for excision in presence of a recombinase, e.g. loxP or FRT

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Environmental Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Position Input By Displaying (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
SM201600229T 2010-06-22 2016-07-13 SMT201600229B (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US35731710P 2010-06-22 2010-06-22
US35731410P 2010-06-22 2010-06-22
EP11728508.0A EP2480675B1 (en) 2010-06-22 2011-06-22 Mice expressing a light chain with human lambda variable and mouse constant regions

Publications (1)

Publication Number Publication Date
SMT201600229B true SMT201600229B (it) 2016-08-31

Family

ID=44509861

Family Applications (5)

Application Number Title Priority Date Filing Date
SM20190241T SMT201900241T1 (it) 2010-06-22 2011-06-22 Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana
SM20170506T SMT201700506T1 (it) 2010-06-22 2011-06-22 Topi transgenici con un locus endogeno di immunoglobulina lambda modificato
SM201600212T SMT201600212B (it) 2010-06-22 2016-07-05 Topi con catena leggera ibrida
SM201600213T SMT201600213B (it) 2010-06-22 2016-07-05 Topi esprimenti una catena leggera comprendente una regione variabile lambda umana e una regione costante di topo
SM201600229T SMT201600229B (it) 2010-06-22 2016-07-13

Family Applications Before (4)

Application Number Title Priority Date Filing Date
SM20190241T SMT201900241T1 (it) 2010-06-22 2011-06-22 Topi esprimenti una catena leggera ibrida di immunoglobulina con una regione variabile umana
SM20170506T SMT201700506T1 (it) 2010-06-22 2011-06-22 Topi transgenici con un locus endogeno di immunoglobulina lambda modificato
SM201600212T SMT201600212B (it) 2010-06-22 2016-07-05 Topi con catena leggera ibrida
SM201600213T SMT201600213B (it) 2010-06-22 2016-07-05 Topi esprimenti una catena leggera comprendente una regione variabile lambda umana e una regione costante di topo

Country Status (30)

Country Link
US (22) US9035128B2 (it)
EP (7) EP3034608B1 (it)
JP (16) JP6009441B2 (it)
KR (16) KR20220150430A (it)
CN (4) CN104342455B (it)
AU (1) AU2011271046B2 (it)
BR (3) BR112012033248A2 (it)
CA (2) CA2803864C (it)
CY (5) CY1117537T1 (it)
DK (5) DK3034608T3 (it)
ES (5) ES2721749T3 (it)
HR (5) HRP20160794T1 (it)
HU (5) HUE030285T2 (it)
IL (12) IL313063A (it)
LT (4) LT3034608T (it)
ME (5) ME02442B (it)
MX (6) MX336344B (it)
MY (6) MY157477A (it)
NO (1) NO2905338T3 (it)
NZ (6) NZ605758A (it)
PL (5) PL2480676T3 (it)
PT (5) PT2480675T (it)
RS (5) RS55037B1 (it)
RU (3) RU2724736C2 (it)
SG (4) SG10201504324UA (it)
SI (5) SI2480675T1 (it)
SM (5) SMT201900241T1 (it)
TR (1) TR201905992T4 (it)
WO (2) WO2011163314A1 (it)
ZA (5) ZA201300063B (it)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
KR101826224B1 (ko) * 2008-09-30 2018-02-06 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
ES2613730T3 (es) 2008-12-18 2017-05-25 Erasmus University Medical Center Rotterdam Animales transgénicos no humanos que expresan anticuerpos humanizados y su uso
US9445581B2 (en) * 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
NZ597481A (en) 2009-07-08 2013-10-25 Kymab Ltd Animal models and therapeutic molecules
NZ631363A (en) 2010-02-08 2016-05-27 Regeneron Pharma Common light chain mouse
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
NZ601171A (en) 2010-03-31 2014-11-28 Ablexis Llc Genetic engineering of non-human animals for the production of chimeric antibodies
PL2480676T3 (pl) * 2010-06-22 2016-10-31 Mysz wykazująca ekspresję hybrydowego łańcucha lekkiego immunoglobuliny
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US10881084B2 (en) 2010-07-26 2021-01-05 Trianni, Inc Transgenic animals and methods of use
NZ707327A (en) * 2010-08-02 2017-01-27 Regeneron Pharma Mice that make binding proteins comprising vl domains
LT3572517T (lt) 2011-08-05 2021-04-26 Regeneron Pharmaceuticals, Inc. Humanizuotos universalios lengvosios grandinės pelės
EP3839049A3 (en) 2011-09-19 2021-10-20 Kymab Limited Antibodies, variable domains & chains tailored for human use
JP2014531452A (ja) * 2011-09-19 2014-11-27 カイマブ・リミテッド 動物、レパートリーおよび方法
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
US9253965B2 (en) * 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
EP3527070B1 (en) * 2011-12-20 2025-12-03 Regeneron Pharmaceuticals, Inc. Humanized light chain mice
DK2825037T3 (da) 2012-03-16 2019-07-29 Regeneron Pharma Gnavere, der udtrykker pH-sensitive immunoglobulinsekvenser
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
SMT201800229T1 (it) 2012-03-16 2018-07-17 Regeneron Pharma Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi
HK1200271A1 (en) 2012-03-16 2015-08-07 瑞泽恩制药公司 Mice that produce antigen-binding proteins with ph-dependent binding characteristics
JP2015512635A (ja) 2012-03-28 2015-04-30 カイマブ・リミテッド クラススイッチした完全ヒト抗体の発現のためのトランスジェニック非−ヒト脊椎動物
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
US20140245468A1 (en) 2013-02-20 2014-08-28 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
ES2712207T3 (es) * 2013-03-13 2019-05-09 Regeneron Pharma Ratones que expresan un repertorio limitado de cadenas ligeras de inmunoglobulina
US9980470B2 (en) 2013-03-14 2018-05-29 Erasmus University Medical Center Antibody production
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US11707056B2 (en) * 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
ES2738679T3 (es) * 2013-09-18 2020-01-24 Regeneron Pharma Anticuerpos de cadena ligera diseñados genéticamente con histidina y animales no humanos modificados genéticamente para generar los mismos
DE112014004537T5 (de) 2013-10-01 2016-07-21 Kymab Limited Tiermodelle und therapeutische Moleküle
TW201532513A (zh) * 2014-01-10 2015-09-01 Alfur Fu-Hsin Hung 能產生比小鼠ＩgＥ量高出許多的人源化ＩgＥ之基因轉殖動物
EP3895528A1 (en) 2014-03-21 2021-10-20 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
KR20160131118A (ko) 2014-03-21 2016-11-15 리제너론 파마슈티칼스 인코포레이티드 상이한 결합 특징을 전시하는 vl 항원 결합 단백질
PT3151921T (pt) 2014-06-06 2019-11-21 Bristol Myers Squibb Co Anticorpos contra recetor do fator de necrose tumoral induzido por glicocorticoide e utilizações dos mesmos
CA2959428A1 (en) 2014-09-19 2016-03-24 Regeneron Pharmaceuticals, Inc. Chimeric antigen receptors
CA2963470A1 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
UY36404A (es) 2014-11-21 2016-06-01 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware ANTICUERPOS MONOCLONALES (Ab) COMO DETECTORES DE CD73 E INHIBIDORES DE SU ACTIVIDAD ENZIMÁTICA, Y COMPOSICIONES QUE LOS CONTIENEN
DK3233912T3 (da) 2014-12-19 2021-08-02 Regenesance B V Antistoffer, der binder human c6, og anvendelser deraf
US10189902B2 (en) 2014-12-23 2019-01-29 Bristol-Myers Squibb Company Antibodies to TIGIT
MA40708B1 (fr) 2015-02-05 2020-12-31 Basf Se Centrale solaire comprenant un premier circuit de caloporteur et un deuxième circuit de caloporteur
EP3271403A1 (en) * 2015-03-19 2018-01-24 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
WO2016196228A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
UY36757A (es) 2015-06-29 2016-12-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada
CN105274116B (zh) * 2015-10-21 2020-09-29 重庆金迈博生物科技有限公司 一种制备人源化抗体的核酸分子及其应用
AU2016356780A1 (en) 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
US10813346B2 (en) 2015-12-03 2020-10-27 Trianni, Inc. Enhanced immunoglobulin diversity
IL260743B2 (en) 2016-02-04 2024-03-01 Trianni Inc Advanced production of antibodies
CA3016187A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
WO2017151176A1 (en) 2016-03-04 2017-09-08 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
MX392069B (es) 2016-05-09 2025-03-21 Bristol Myers Squibb Co Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
RU2745563C2 (ru) 2016-05-20 2021-03-29 Регенерон Фармасьютикалс, Инк. Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
RS66700B1 (sr) 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
WO2017214089A1 (en) * 2016-06-06 2017-12-14 Regeneron Pharmaceuticals, Inc. Non-human animals expressing antibodies with human lambda light chains
US20170372142A1 (en) * 2016-06-27 2017-12-28 Facebook, Inc. Systems and methods for identifying matching content
BR112019000431A2 (pt) 2016-07-14 2019-07-09 Bristol-Myers Squibb Company anticorpos contra tim3 e usos dos mesmos
US10981976B2 (en) 2016-08-31 2021-04-20 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus K envelope (HERV-K) and use thereof
EP3525815A2 (en) 2016-10-13 2019-08-21 Massachusetts Institute of Technology Antibodies that bind zika virus envelope protein and uses thereof
AU2017348743C1 (en) 2016-10-31 2022-03-03 National University Corporation Tottori University Human antibody–producing non-human animal and method for preparing human antibodies using same
SI3766343T1 (sl) * 2016-11-04 2022-06-30 Regeneron Pharmaceuticals, Inc. Nehumane živali z modificiranim lokusom lahke verige lambda imunoglobulina
EA201991720A1 (ru) 2017-02-17 2020-01-20 Бристол-Маерс Сквибб Компани Антитела к альфа-синуклеину и их применения
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
ES2928995T3 (es) 2017-12-05 2022-11-24 Regeneron Pharma Ratones que tienen una cadena ligera lambda de inmunoglobulina genomanipulada y usos de los mismos
CN111886255B (zh) 2018-01-12 2025-04-04 百时美施贵宝公司 抗tim3抗体及其用途
CA3093407A1 (en) 2018-03-23 2019-09-26 Bristol-Myers Squibb Company Antibodies against mica and/or micb and uses thereof
SMT202500038T1 (it) 2018-03-24 2025-03-12 Regeneron Pharma Topi o ratti geneticamente modificati per la generazione di anticorpi terapeutici contro complessi peptide-mhc, metodi di produzione e loro utilizzo
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
EP3813521B1 (en) * 2018-06-08 2025-03-05 Crystal Bioscience Inc. Transgenic chicken for producing diversified antibodies that have the same light chain ii
IL318469A (en) 2018-06-14 2025-03-01 Regeneron Pharma Non-human animals capable of reorganizing transgenic DH-DH, and their uses
EP3872506A4 (en) 2018-10-26 2023-01-11 Vehicle Energy Japan Inc. Battery control device
AU2019380307B2 (en) 2018-11-16 2026-01-29 Bristol-Myers Squibb Company Anti-NKG2A antibodies and uses thereof
CN118894938A (zh) 2019-01-22 2024-11-05 百时美施贵宝公司 抗IL-7Rα亚基的抗体及其用途
AU2020226865A1 (en) 2019-02-22 2021-07-29 Regeneron Pharmaceuticals, Inc. Rodents having genetically modified sodium channels and methods of use thereof
CA3136478A1 (en) * 2019-06-05 2020-12-10 Regeneron Pharmaceuticals, Inc. Non-human animals having a limited lambda light chain repertoire expressed from the kappa locus and uses thereof
WO2021003152A1 (en) * 2019-07-01 2021-01-07 Trianni, Inc. Transgenic mammals and methods of use thereof
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
US20230192867A1 (en) 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
KR20230024822A (ko) * 2020-06-25 2023-02-21 주식회사 휴맵 이형접합성 형질전환 동물
AU2021342159A1 (en) 2020-09-11 2023-03-02 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CN116848254A (zh) 2020-12-16 2023-10-03 瑞泽恩制药公司 表达人源化Fcα受体的小鼠
US12371487B2 (en) 2020-12-23 2025-07-29 Regeneron Pharmaceuticals, Inc. Methods for obtaining antibodies that bind transmembrane proteins and cells that produce the same
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
WO2023199655A1 (ja) 2022-04-13 2023-10-19 日本精工株式会社 軸受装置の状態の検出方法、検出装置、およびプログラム
USD999969S1 (en) * 2022-04-29 2023-09-26 Shenzhen Intellirocks Tech. Co., Ltd. Lamp
EP4658687A1 (en) 2023-01-31 2025-12-10 University of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections
WO2024229461A2 (en) 2023-05-04 2024-11-07 Novasenta, Inc. Anti-cd161 antibodies and methods of use thereof
WO2025184208A1 (en) 2024-02-27 2025-09-04 Bristol-Myers Squibb Company Anti-ceacam5 antibodies and uses thereof
WO2026030428A2 (en) 2024-08-01 2026-02-05 Regeneron Pharmaceuticals, Inc. Prostate-specific antigen peptides and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
CA2078539C (en) * 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
JP4215172B2 (ja) * 1996-12-03 2009-01-28 アムジェン フレモント インク． 複数のＶ▲下Ｈ▼およびＶ▲下κ▼領域を含むヒトＩｇ遺伝子座を有するトランスジェニック哺乳動物、ならびにそれから産生される抗体
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
RU2262511C2 (ru) * 2000-05-18 2005-10-20 Джапан Тобакко, Инк. Человеческое моноклональное антитело против ailim, костимулирующей молекулы передачи сигнала, и его фармацевтическое применение
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
IL155977A0 (en) * 2000-11-30 2003-12-23 Medarex Inc Transgenic transchromosomal rodents for making human antibodies
GB0031284D0 (en) * 2000-12-21 2001-01-31 Ks Biomedix Ltd High affinity antibodies
DE60227067D1 (de) * 2001-05-11 2008-07-24 Kirin Pharma Kk Künstliches menschliches chromosom mit dem gen für die lambda-leichte kette menschlicher antikörper
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
DK2319301T3 (en) 2001-11-30 2017-12-04 Amgen Fremont Inc Transgenic animals with human Ig lambda light chain genes
US20030217171A1 (en) 2002-05-17 2003-11-20 Von Stuermer Wolfgang R. Self-replicating and self-installing software apparatus
MXPA06000562A (es) * 2003-07-15 2006-03-30 Therapeutic Human Polyclonals Loci de inmunoglobulina humanizada.
CN1605628A (zh) * 2003-09-03 2005-04-13 中国疾病预防控制中心病毒病预防控制所 Cho细胞生产的人源抗甲肝病毒基因工程抗体
US7476724B2 (en) * 2004-08-05 2009-01-13 Genentech, Inc. Humanized anti-cmet antibodies
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
DE602005026571D1 (de) * 2004-12-29 2011-04-07 Yuhan Corp Tumornekrosefaktor-alpha spezifische humanisierte antikörper
US7910798B2 (en) 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN101501073A (zh) * 2006-08-22 2009-08-05 G2英弗勒美欣私人有限公司 抗体制备方法
RS53340B (sr) 2006-10-02 2014-10-31 Regeneron Pharmaceuticals, Inc. Humana antitela visokog afiniteta za humani il-4 receptor
US7864492B2 (en) 2006-10-31 2011-01-04 Siemens Industry, Inc. Systems and methods for arc fault detection
DE102007045897A1 (de) 2007-09-26 2009-04-09 Carl Zeiss Microimaging Gmbh Verfahren zur mikroskopischen dreidimensionalen Abbildung einer Probe
WO2009129247A2 (en) * 2008-04-14 2009-10-22 Innovative Targeting Solutions Inc. Sequence diversity generation in immunoglobulins
EP2288623B1 (en) 2008-05-23 2013-07-10 Ablexis, LLC Method of generating single vl domain antibodies in transgenic animals
KR101826224B1 (ko) 2008-09-30 2018-02-06 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
ES2613730T3 (es) * 2008-12-18 2017-05-25 Erasmus University Medical Center Rotterdam Animales transgénicos no humanos que expresan anticuerpos humanizados y su uso
NZ597481A (en) 2009-07-08 2013-10-25 Kymab Ltd Animal models and therapeutic molecules
NZ631363A (en) * 2010-02-08 2016-05-27 Regeneron Pharma Common light chain mouse
SG186238A1 (en) 2010-06-17 2013-01-30 Kymab Ltd Animal models and therapeutic molecules
PL2480676T3 (pl) * 2010-06-22 2016-10-31 Mysz wykazująca ekspresję hybrydowego łańcucha lekkiego immunoglobuliny

Also Published As

Publication number Publication date
US9850462B2 (en) 2017-12-26
CA2804311A1 (en) 2011-12-29
NZ605751A (en) 2014-10-31
NO2905338T3 (it) 2017-12-30
RU2724736C2 (ru) 2020-06-25
JP2021061863A (ja) 2021-04-22
KR20200143511A (ko) 2020-12-23
PT2480676E (pt) 2016-06-09
CN103068994B (zh) 2016-01-20
JP6963542B2 (ja) 2021-11-10
KR20200064166A (ko) 2020-06-05
US20190153384A1 (en) 2019-05-23
AU2011271043B2 (en) 2015-10-01
DK2480676T3 (en) 2016-06-20
CY1122877T1 (el) 2021-05-05
DK2568049T3 (en) 2016-08-01
KR102462042B1 (ko) 2022-11-03
IL255179B (en) 2018-06-28
TR201905992T4 (tr) 2019-05-21
US9334333B2 (en) 2016-05-10
ZA201404600B (en) 2015-09-30
IL300712B1 (en) 2024-07-01
ZA201506598B (en) 2017-03-29
EP2480675B1 (en) 2016-04-06
US9012717B2 (en) 2015-04-21
CA2803864C (en) 2017-05-16
US9206261B2 (en) 2015-12-08
PT2480675T (pt) 2016-07-11
KR20220150430A (ko) 2022-11-10
IL223719A (en) 2016-10-31
KR20130027555A (ko) 2013-03-15
KR101934852B1 (ko) 2019-01-04
HRP20160497T1 (hr) 2016-07-15
SI2480676T1 (sl) 2016-10-28
KR102211911B1 (ko) 2021-02-05
SI2905338T1 (sl) 2017-12-29
SG186391A1 (en) 2013-01-30
RU2016119423A3 (it) 2019-11-19
US9066502B2 (en) 2015-06-30
CN103068993A (zh) 2013-04-24
SMT201600212B (it) 2016-08-31
US9006511B2 (en) 2015-04-14
KR20180135997A (ko) 2018-12-21
HUE030285T2 (en) 2017-05-29
CN104342455B (zh) 2017-05-31
EP2905338B8 (en) 2018-01-24
JP5988969B2 (ja) 2016-09-07
JP2017006152A (ja) 2017-01-12
HRP20160794T1 (hr) 2016-08-12
JP6073441B2 (ja) 2017-02-01
IL291301A (en) 2022-05-01
CA2803864A1 (en) 2011-12-29
DK3034608T3 (da) 2019-05-06
KR20130121814A (ko) 2013-11-06
LT2568049T (lt) 2016-10-10
ME02902B (me) 2018-04-20
JP2018201528A (ja) 2018-12-27
HUE029691T2 (en) 2017-03-28
EP2480675A1 (en) 2012-08-01
SG10201504324UA (en) 2015-07-30
AU2011271046A1 (en) 2013-01-31
US9029628B2 (en) 2015-05-12
PL2905338T3 (pl) 2018-01-31
US9399683B2 (en) 2016-07-26
EP2480676B1 (en) 2016-04-06
CN103068993B (zh) 2016-01-06
NZ605758A (en) 2014-08-29
IL313063A (en) 2024-07-01
IL269078B (en) 2021-05-31
IL282872B (en) 2022-04-01
JP2017012204A (ja) 2017-01-19
DK2905338T3 (da) 2017-11-06
US9163092B2 (en) 2015-10-20
MY194456A (en) 2022-11-30
CY1118126T1 (el) 2017-06-28
ES2721749T3 (es) 2019-08-05
HK1168384A1 (zh) 2012-12-28
AU2011271043A8 (en) 2016-01-21
NZ626979A (en) 2015-05-29
ZA201404601B (en) 2016-02-24
US20240327785A1 (en) 2024-10-03
EP2905338B1 (en) 2017-08-02
PL3034608T3 (pl) 2019-08-30
RS54891B1 (sr) 2016-10-31
JP2013532974A (ja) 2013-08-22
JP2022066449A (ja) 2022-04-28
KR102193823B1 (ko) 2020-12-22
ES2570131T3 (es) 2016-05-17
ME02444B (me) 2016-09-20
SMT201600213B (it) 2016-08-31
PL2568049T3 (pl) 2017-03-31
PL2480675T3 (pl) 2017-03-31
PT2568049T (pt) 2016-07-11
US20160060359A1 (en) 2016-03-03
RS55042B1 (sr) 2016-12-30
RS58736B1 (sr) 2019-06-28
MX2012015298A (es) 2013-05-01
US9206263B2 (en) 2015-12-08
LT2480675T (lt) 2016-10-10
RU2601297C2 (ru) 2016-10-27
CY1119478T1 (el) 2018-03-07
KR102266097B1 (ko) 2021-06-18
PT2905338T (pt) 2017-11-10
HRP20190807T1 (hr) 2019-08-23
US9150662B2 (en) 2015-10-06
RU2013102596A (ru) 2014-07-27
SG186390A1 (en) 2013-01-30
LT2905338T (lt) 2017-12-27
MY165287A (en) 2018-03-21
IL282872A (en) 2021-06-30
US20130323790A1 (en) 2013-12-05
ES2575223T3 (es) 2016-06-27
IL264634B (en) 2019-09-26
JP6243384B2 (ja) 2017-12-06
MY157477A (en) 2016-06-15
MX2022002117A (es) 2022-03-17
EP3034608A1 (en) 2016-06-22
JP2018023403A (ja) 2018-02-15
US20170107484A1 (en) 2017-04-20
CN104404050B (zh) 2018-06-08
KR101975884B1 (ko) 2019-05-10
LT3034608T (lt) 2019-05-27
IL244450A (en) 2017-11-30
KR102320944B1 (ko) 2021-11-04
SI3034608T1 (sl) 2019-06-28
SMT201900241T1 (it) 2019-05-10
BR112012033248A2 (pt) 2017-11-28
AU2011271046B2 (en) 2015-10-01
KR102001430B1 (ko) 2019-07-18
EP3456832A1 (en) 2019-03-20
NZ627119A (en) 2015-05-29
MX348942B (es) 2017-07-04
JP6341972B2 (ja) 2018-06-13
ME02440B (me) 2016-09-20
PT3034608T (pt) 2019-05-28
KR20190014576A (ko) 2019-02-12
RU2016119423A (ru) 2018-11-07
MX2012015300A (es) 2013-05-01
HK1226766A1 (en) 2017-10-06
KR20190014578A (ko) 2019-02-12
BR112012032991A2 (pt) 2015-10-06
US20150173332A1 (en) 2015-06-25
NZ707200A (en) 2016-04-29
IL244450A0 (en) 2016-04-21
IL259965A (en) 2018-07-31
MX347318B (es) 2017-04-21
EP3205726A1 (en) 2017-08-16
JP2013531501A (ja) 2013-08-08
KR20190073584A (ko) 2019-06-26
US9540452B2 (en) 2017-01-10
EP3034608B1 (en) 2019-01-30
KR101945352B1 (ko) 2019-02-07
EP2568049B1 (en) 2016-04-13
MY195212A (en) 2023-01-11
US20150246976A1 (en) 2015-09-03
MY195214A (en) 2023-01-11
WO2011163314A1 (en) 2011-12-29
US20150176002A1 (en) 2015-06-25
RU2013102595A (ru) 2014-07-27
IL223720A (en) 2017-05-29
EP2568049A1 (en) 2013-03-13
MY195217A (en) 2023-01-11
US20140137275A1 (en) 2014-05-15
ME03386B (me) 2020-01-20
EP2905338A1 (en) 2015-08-12
US9035128B2 (en) 2015-05-19
US9226484B2 (en) 2016-01-05
US9844212B2 (en) 2017-12-19
JP2025027148A (ja) 2025-02-26
IL255179A0 (en) 2017-12-31
SI2568049T1 (sl) 2016-10-28
KR102506001B1 (ko) 2023-03-07
KR101970944B1 (ko) 2019-04-23
HK1170766A1 (zh) 2013-03-08
US20150246977A1 (en) 2015-09-03
JP6009441B2 (ja) 2016-10-19
IL291301B2 (en) 2023-07-01
JP2016010417A (ja) 2016-01-21
HRP20171666T1 (hr) 2017-12-15
BR112012032991B1 (pt) 2021-08-10
JP2019033765A (ja) 2019-03-07
ES2646052T3 (es) 2017-12-11
MX336344B (es) 2016-01-15
HUE044001T2 (hu) 2019-09-30
CY1117537T1 (el) 2017-04-26
CA2804311C (en) 2017-09-12
RS56589B1 (sr) 2018-02-28
BR122020013427B1 (pt) 2021-08-03
JP2020128440A (ja) 2020-08-27
MX347322B (es) 2017-04-21
KR101991234B1 (ko) 2019-06-20
CN104342455A (zh) 2015-02-11
KR20230036157A (ko) 2023-03-14
KR20180135996A (ko) 2018-12-21
AU2011271043A9 (en) 2015-10-01
KR20210073609A (ko) 2021-06-18
CN104404050A (zh) 2015-03-11
US20150173331A1 (en) 2015-06-25
DK2480675T3 (en) 2016-08-01
KR102118565B1 (ko) 2020-06-03
RU2590594C2 (ru) 2016-07-10
CY1117692T1 (el) 2017-05-17
KR20210134424A (ko) 2021-11-09
ZA201300063B (en) 2014-09-25
US20170258059A1 (en) 2017-09-14
US20200239837A1 (en) 2020-07-30
US20150351371A1 (en) 2015-12-10
US9206262B2 (en) 2015-12-08
JP7236409B2 (ja) 2023-03-09
US10266803B2 (en) 2019-04-23
US20180064078A1 (en) 2018-03-08
ES2576928T3 (es) 2016-07-12
SG10201504568YA (en) 2015-07-30
US20150320023A1 (en) 2015-11-12
HK1183321A1 (en) 2013-12-20
KR20190049932A (ko) 2019-05-09
PL2480676T3 (pl) 2016-10-31
JP6545773B2 (ja) 2019-07-17
US20120073004A1 (en) 2012-03-22
WO2011163311A1 (en) 2011-12-29
JP2023133554A (ja) 2023-09-22
US20190203171A1 (en) 2019-07-04
HUE029692T2 (en) 2017-03-28
KR20210013376A (ko) 2021-02-03
SI2480675T1 (sl) 2016-08-31
KR20190142436A (ko) 2019-12-26
IL300712B2 (en) 2024-11-01
IL291301B1 (en) 2023-03-01
ME02442B (me) 2016-09-20
IL247386A (en) 2017-07-31
NZ707198A (en) 2016-04-29
EP2480676A1 (en) 2012-08-01
CN103068994A (zh) 2013-04-24
ZA201300062B (en) 2014-09-25
AU2011271043A1 (en) 2013-01-31
KR102059909B1 (ko) 2019-12-27
HUE036597T2 (hu) 2018-07-30
US20160057979A1 (en) 2016-03-03
HRP20160865T1 (hr) 2016-10-07
RS55037B1 (sr) 2016-12-30
IL259965B (en) 2019-02-28
JP2018201527A (ja) 2018-12-27
BR112012032991A8 (pt) 2020-09-29
US20130326647A1 (en) 2013-12-05
US20120070861A1 (en) 2012-03-22
IL300712A (en) 2023-04-01
JP2016010415A (ja) 2016-01-21
SMT201700506T1 (it) 2018-01-11
US20150089680A1 (en) 2015-03-26
US9394373B2 (en) 2016-07-19
JP2020062061A (ja) 2020-04-23
IL269078A (en) 2019-11-28

Similar Documents

Publication Publication Date Title
BR112013008959A2 (it)
BR112012030039A2 (it)
BR112012028408A2 (it)
BR112012029986A2 (it)
BR112012027808A2 (it)
BR112012026492A2 (it)
BR112012031500A2 (it)
BR112012025307A2 (it)
BR112012002126A2 (it)
BR112012026946A2 (it)
BR112012025482A2 (it)
BR112013006400A2 (it)
BR112012031826A2 (it)
BR112012028186A2 (it)
BR112012025577A2 (it)
BR112012016456A2 (it)
BR112012027015A2 (it)
BR112012025308A2 (it)
BR112013010949A2 (it)
BR112012027945A2 (it)
BR112012026403A2 (it)
BR112013002646A2 (it)
BR112013012726A2 (it)
BR112012016895A2 (it)
BR112013006825A2 (it)